2024-12-09 04:59:00 ET
According to a sneak peek of the data from one of Eli Lilly 's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk , (NYSE: NVO) and it isn't the first time.
Here's why the stock is worth investing in even more than before.
One of the most important questions about the competitive prospects of Lilly against Novo Nordisk in the market for anti-obesity medicines is, quite simply, which company makes the more effective drug.
